Literature DB >> 2954477

Transluminal angioplasty versus surgical repair for stenosis of hemodialysis grafts. A randomized study.

J L Brooks, R D Sigley, K J May, R M Mack.   

Abstract

A randomized study of transluminal angioplasty versus surgical revision for stenosis at the venous end of hemodialysis grafts was carried out. Median patency for the surgical group was 12 months versus only 4 months for the transluminal angioplasty group. This difference was statistically significant (p less than 0.01). In addition, the average cost for surgical revision was slightly less than that for transluminal angioplasty. Therefore, for long-term patency, surgical treatment is the method of choice, although under special circumstances there may still be a role for transluminal angioplasty.

Mesh:

Year:  1987        PMID: 2954477     DOI: 10.1016/0002-9610(87)90148-6

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  4 in total

1.  Surgical thrombectomy for thrombosed dialysis grafts: comparison of adjunctive treatments.

Authors:  Yun-Hen Liu; Yen-Ni Hung; Hung-Chang Hsieh; Po-Jen Ko
Journal:  World J Surg       Date:  2007-12-08       Impact factor: 3.352

2.  Pharmacomechanical Thrombolysis of Dialysis Access Grafts Using the MTI Castañeda Over-the-Wire Brush Catheter and Reteplase.

Authors:  Alexjandro Mendez-Castillo; Syed Hassain; Flavio Castañeda
Journal:  Semin Intervent Radiol       Date:  2004-06       Impact factor: 1.513

Review 3.  Pre-emptive correction for haemodialysis arteriovenous access stenosis.

Authors:  Pietro Ravani; Robert R Quinn; Matthew J Oliver; Divya J Karsanji; Matthew T James; Jennifer M MacRae; Suetonia C Palmer; Giovanni F M Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2016-01-07

4.  Follow-up results after stent placement in failing arteriovenous shunts: a three-year experience.

Authors:  D Vorwerk; R W Günther; K Bohndorf; D Kistler; U Gladziwa; H G Sieberth
Journal:  Cardiovasc Intervent Radiol       Date:  1991 Sep-Oct       Impact factor: 2.740

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.